Merck Completes Acquisition of JSR Life Sciences' Chromatography Business, Strengthening Protein A Technology and Expanding Downstream Portfolio
NQ Score
100/100
AI Summary (NQ-processed)
Merck has completed the acquisition of JSR Life Sciences' chromatography business, integrating advanced Protein A technology and Amsphere™ Protein A resins into its downstream process portfolio. This acquisition strengthens Merck's ability to support the efficient and scalable purification of monoclonal antibodies, helping customers improve productivity and accelerate access to critical therapeutics. Over 50 employees from the acquired Belgian chromatography unit will join Merck, enhancing its global technical support and application expertise in biopharmaceutical manufacturing.
AI analysis data is not yet available.